ArticleJCEM case reports2026
Progression from Stage 1 to Stage 3 Type 1 Diabetes Characterized by Hypoglycemia.
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Letter to the editor from Thea and Buschard: "Progression from stage 1 to stage 3 type 1 diabetes characterized by hypoglycemia".JCEM case reports · 2026Article
- Response to letter to the editor from Thea and Buschard: "Progression from stage 1 to stage 3 type 1 diabetes characterized by hypoglycemia".JCEM case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Type 1 diabetes (T1D) development progresses through well-defined stages based on the presence of islet autoantibodies such as insulin autoantibody, glutamic acid decarboxylase autoantibody, tyrosine phosphatase-like protein IA-2 autoantibody, and zinc transporter 8 autoantibody and glycemic status. The presence of multiple islet autoantibodies and normal glucose tolerance is considered stage 1 T1D. Progression to abnormal glucose tolerance, as measured by oral glucose tolerance test or hemoglobin A1c, is considered stage 2, and stage 3 T1D is defined by symptomatic hyperglycemia and the need for insulin replacement therapy. Here, we present a case of a 9-year-old male with rapid progression from stage 1 T1D to stage 3 T1D characterized by persistent, symptomatic hypoglycemia, concurrent with abnormal glucose tolerance. This case demonstrates the paradoxical presence of hypoglycemia and impaired glucose tolerance and suggests that hypoglycemia may be a biomarker of imminent and rapid progression to stage 3 T1D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.